Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection

Clin Transplant. 2003 Feb;17(1):69-74. doi: 10.1034/j.1399-0012.2003.02105.x.

Abstract

Acute steroid-resistant rejection episodes are recommended to be treated with set doses of anti-thymocyte globulin (ATG) or anti-CD3 monoclonal antibody (OKT3). Individualized T cell monitoring has been proposed as a tool for dose finding. A randomized study comparing the efficacy and safety of ATG (n = 27) with OKT3 (n = 28) in the treatment of biopsy verified acute steroid-resistant rejection (ASRR) when both drugs were administered on the basis of daily individualized T cell measurements. A drop to below 50 cells/mm3 CD2+ T cells was considered adequate and used to guide the dose of ATG/OKT3. Demographic, clinical and histopathological severities of rejections were equal in the two groups. During the 10 days of T cell monitoring and antibody treatment, 13 patients were in need of dialysis (ATG = 7/OKT3 = 6). Two grafts did not respond to antibody treatment and were lost due to rejection (ATG = 1/OKT3 = 1). There were 26 biopsy verified re-rejections (ATG = 12/OKT3 = 14) within the first 3 months following antibody treatment. Mean serum creatinine (micromol/L) was similar in the two groups (ATG/OKT3: before rejection 157 +/- 72/151 +/- 88, at start of antibody treatment 308 +/- 125/330 +/- 94, end of antibody treatment 254 +/- 122/246 +/- 144 and at follow-up after a mean of 32 months 166 +/- 55 (n = 24)/164 +/- 57(n = 23)). To keep the T cell count below 50 cells/mm3, average dose ATG given was 354 +/- 151 mg (2.3 administrations, range 1-4) and average OKT3 was 32.5 +/- 6.8 mg in 10 doses. In conclusion, individualized T cell monitored administration of ATG and OKT3 is safe and seems as effective as a standard set dose in treatment of ASRR. Tailoring the dose for each individual patient lowers the cost.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antilymphocyte Serum / administration & dosage*
  • Dose-Response Relationship, Immunologic
  • Drug Resistance
  • Female
  • Graft Rejection / drug therapy*
  • Humans
  • Immunosuppression Therapy / methods
  • Kidney Transplantation / immunology*
  • Male
  • Middle Aged
  • Muromonab-CD3 / administration & dosage*
  • Prospective Studies
  • Statistics, Nonparametric
  • Steroids / administration & dosage
  • T-Lymphocytes / immunology*
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Muromonab-CD3
  • Steroids